
vTv Therapeutics (VTVT) Stock Forecast & Price Target
vTv Therapeutics (VTVT) Analyst Ratings
Bulls say
vTv Therapeutics is a promising company in the biopharmaceutical industry, particularly in the field of diabetes treatment. With its lead candidate cadisegliatin, which has Breakthrough Therapy Designation, vTv is well-positioned to potentially address the unmet need for safe and effective adjunctive therapies for type 1 diabetes. The company has a strong clinical pipeline and strategic collaborations to support its growth, and its financials, while showing some increase in operating expenses, are still sufficient to fund operations for several years. With a potential peak sales estimate of $840M and upcoming Phase 3 trial completion and readout, vTv Therapeutics has a positive outlook for potential future success.
Bears say
vTv Therapeutics is a late-stage biopharmaceutical company with a pipeline focused on metabolic diseases, specifically type 1 diabetes. However, recent clinical trials have shown mixed results and the company faces competition from emerging curative treatments for T1D, limiting the potential market for their drug. There is also uncertainty around the long-term efficacy and safety of their lead drug, cadisegliatin, and as a result, the stock may face volatility in the short-term. Financially, the company has a high cash burn rate and limited revenue streams, potentially putting them at risk for future funding needs.
This aggregate rating is based on analysts' research of vTv Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
vTv Therapeutics (VTVT) Analyst Forecast & Price Prediction
Start investing in vTv Therapeutics (VTVT)
Order type
Buy in
Order amount
Est. shares
0 shares